Celgene and Agios Win Prix Galien

Rewarding Collaborative Research

One of Celgene’s defining characteristics has been a unique distributed research model, supporting promising programs from cutting-edge partners to advance new medicines for patients. In this model, Celgene and its partners mutually benefit from the resources, expertise and innovation from each entity.

One of the longest-standing examples of this collaborative strategy at work is the partnership between Celgene and Agios Pharmaceuticals, Inc., which began in 2010. The Celgene and Agios collaboration has encompassed research and development across a range of candidates in metabolic immuno-oncology and, importantly, led to the 2017 U.S. FDA approval of IDHIFA® (enasidenib) –the first approved medicine from the Celgene distributed research model.

Now, IDHIFA has earned another distinction – Prix Galien winner. IDHIFA was named the 2018 Best Pharmaceutical Product at the 12th annual Prix Galien Awards Gala on October 25 in New York City.

Presented by the Galien Foundation, the Prix Galien is an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies and is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

“All winners have made crucial contributions to the advancement of scientific understanding and improved outcomes for humankind,” said Bruno Cohen, Chairman of the Galien Foundation in a statement. “We are proud to honor their tireless work and unrelenting spirit.”

The road to this signature award reflects the shared commitment to patients at both Celgene and Agios. Working closely from the discovery stage, the companies evaluated potential candidates, conducted pre-clinical and clinical research, and ultimately achieved a U.S. approval and launch – less than four years from the first patient ever being dosed with IDHIFA. The companies share commercialization of IDHIFA.

“For all of us at Agios, it is truly an incredible honor to receive the 2018 Prix Galien Award with Celgene for IDHIFA for Best Pharmaceutical Product. As one of the highest accolades for pharmaceutical research and development, this award recognizes the extraordinary, collaborative effort that led to the creation of this important medicine,” said David Schenkein, M.D., Chief Executive Officer of Agios. “This feat would not be possible without the support of our partner Celgene, the patients who participated in our clinical trial, and the Agios scientists who made the IDH discovery and created the IDHIFA molecule.”

“The Celgene and Agios teams have spent years working together toward a common goal,” said Nadim Ahmed, President of Hematology/Oncology for Celgene. “The Prix Galien award is a recognition that our shared commitment has a meaningful impact on the lives of patients.”

“The Celgene and Agios team represent the very best attributes of collaboration,” said Krishnan Viswanadhan, Vice President of Global Alliances for Celgene, who accepted the Prix Galien on behalf of the team alongside Dr. Schenkein. “The combination of Agios’ pioneering science and Celgene’s deep experience in blood cancer research created tremendous potential for innovation, and the drive to help patients constantly pushed us to deliver.”

The Prix Galien award for IDHIFA recognizes, first and foremost, the significant potential to help change outcomes for patients, but also the value and importance of great partnerships.

Please see full Prescribing Information, including Boxed WARNING, for IDHIFA®